Soltis Investment Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY – Get Rating) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 742 shares of the company’s stock, valued at approximately $241,000.
Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Eli Lilly and by 1.8% during the first quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after acquiring an additional 1,219,424 shares in the last quarter. Capital World Investors boosted its position in shares of Eli Lilly and by 17.0% during the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after buying an additional 3,242,548 shares during the last quarter. Jennison Associates LLC raised its position in Eli Lilly and by 31.1% in the 2nd quarter. Jennison Associates LLC now owns 10,358,066 shares of the company’s stock valued at $3,358,396,000 after buying an additional 2,456,760 shares during the last quarter. Capital International Investors lifted its stake in Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock valued at $2,532,024,000 after acquiring an additional 2,063,557 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Eli Lilly and by 7.5% during the 1st quarter. Fisher Asset Management LLC now owns 7,504,205 shares of the company’s stock worth $2,148,979,000 after acquiring an additional 521,295 shares during the last quarter. 82.45% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 400 shares of the company’s stock in a transaction dated Wednesday, October 12th. The stock was sold at an average price of $333.50, for a total value of $133,400.00. Following the transaction, the insider now directly owns 103,624,146 shares in the company, valued at approximately $34,558,652,691. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Alonzo Weems sold 656 shares of the firm’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $326.23, for a total transaction of $214,006.88. Following the sale, the executive vice president now owns 6,950 shares in the company, valued at approximately $2,267,298.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 400 shares of the company’s stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $333.50, for a total transaction of $133,400.00. Following the completion of the transaction, the insider now owns 103,624,146 shares of the company’s stock, valued at $34,558,652,691. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 571,297 shares of company stock worth $193,929,777. Corporate insiders own 0.12% of the company’s stock.
Eli Lilly and Price Performance
Eli Lilly and Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be issued a $0.98 dividend. The ex-dividend date of this dividend is Monday, November 14th. This represents a $3.92 annualized dividend and a dividend yield of 1.08%. Eli Lilly and’s payout ratio is currently 58.86%.
Analyst Ratings Changes
LLY has been the topic of a number of recent analyst reports. SVB Leerink raised their price target on shares of Eli Lilly and from $341.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, November 2nd. Morgan Stanley cut their price objective on Eli Lilly and from $441.00 to $436.00 and set an “overweight” rating on the stock in a research report on Thursday. Wells Fargo & Company boosted their price target on shares of Eli Lilly and from $305.00 to $365.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 2nd. UBS Group upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $335.00 to $363.00 in a report on Thursday, September 22nd. Finally, StockNews.com began coverage on shares of Eli Lilly and in a research report on Wednesday, October 12th. They set a “buy” rating for the company. Three analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $355.89.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.